June 2017 FDA Recall Drug by Lucid Pharma Llc
D-0921-2017 - Failed Tablet/Capsules Specifications
This Class II drug recall was voluntarily initiated by Lucid Pharma Llc on June 1, 2017 for the product Drug. The FDA reported the reason for recall as failed tablet/capsules specifications. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-0921-2017
Failed Tablet/Capsules Specifications: pharmacists complaints for bottles containing melted capsules.
06-01-2017
06-28-2017
a) 44168 bottles; b) 24960 bottles
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Lucid Pharma LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Nationwide in the USA
09-25-2019
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Venlafaxine Hydrochloride Extended-Release Capsules USP, 75 mg, packaged in a) 30-count bottles (NDC 52343-132-30) and b) 90-count bottles (NDC 52343-132-90), Rx only, Distributed by: Lucid Pharma LLC, 2 Tower Center Blvd, Suite-1101-B, East Brunswick, NJ 08816 USA.
Batch or Lot Expiration Information
Lot# : a) V17516045-A, Exp 08/18; b) V17516047-A 09/18